LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex® (cannabidiol or CBD) […]

by

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (KALY.V), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera […]

by

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera […]

by

Equities researchers at Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $135.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 17.64% from the stock’s current price. The […]

by

Many parents come to my office seeking help for their children suffering with autism.   The three main symptoms that are challenging for these families are communication difficulties, repetitive behaviors, and social challenges, including tantrums and self-injurious behavior.  Although the FDA has approved two medications, both antipsychotics, for treating the irritability associated with autism, they have […]

by

In the Phase 3 of the clinical trials conducted by GW Pharmaceuticals and the Ohio State University on the effectiveness of Epidiolex, results showed that the cannabis-based drug lowered the number of epileptic seizures experienced by children with Lennox-Gastaut syndrome by half. What Is Lennox-Gastaut Syndrome? The Lennox-Gastaut syndrome is one of the rare forms […]

by

Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Thursday morning. The firm issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are […]

by

In the Phase 3 of the clinical trials conducted by GW Pharmaceuticals and the Ohio State University on the effectiveness of Epidiolex, results showed that the cannabis-based drug lowered the number of epileptic seizures experienced by children with Lennox-Gastaut syndrome by half. What Is Lennox-Gastaut Syndrome? The Lennox-Gastaut syndrome is one of the rare forms […]

by

Home » Brain Function » Cannabidiol seen to provide overall improvement for severe epilepsy patients By: Dr. Victor Marchione | Brain Function | Friday, April 21, 2017 – 05:00 AM Seizures are often dramatized on television and in movies—they depict a person collapsing to the ground while they convulse (shake), contracting every muscle in their […]

by